{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T04:33:59Z","timestamp":1773376439071,"version":"3.50.1"},"reference-count":17,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>We report a patient with hepatosplenic T-cell lymphoma (HSTL) and compare the disease to the derived xenograft model. Enhancer of zeste homolog 2 (EZH2) inhibitor treatment of an EZH2-mutant HSTL patient-derived xenograft model led to prolonged survival.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001256","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T16:25:31Z","timestamp":1585671931000},"page":"1265-1269","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-0216","authenticated-orcid":false,"given":"Yana","family":"Pikman","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy Saur","family":"Conway","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda L.","family":"Robichaud","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Kitara","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4835-5770","authenticated-orcid":false,"given":"Alanna J.","family":"Church","sequence":"first","affiliation":[{"name":"Department of Pathology, Boston Children\u2019s Hospital, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-5933","authenticated-orcid":false,"given":"Alyssa L.","family":"Kennedy","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis B.","family":"Silverman","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy L.","family":"Billett","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-3907","authenticated-orcid":false,"given":"David M.","family":"Weinstock","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian H.","family":"Harris","sequence":"first","affiliation":[{"name":"Department of Pathology, Boston Children\u2019s Hospital, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Stegmaier","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology and"},{"name":"Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"issue":"13","key":"2020033111374482800_B1","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"issue":"24","key":"2020033111374482800_B2","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1182\/blood-2011-12-396150","article-title":"Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets","volume":"119","author":"Travert","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2020033111374482800_B3","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.leu.2400742","article-title":"Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic gammadelta T cell lymphoma","volume":"11","author":"Alonsozana","year":"1997","journal-title":"Leukemia"},{"issue":"4","key":"2020033111374482800_B4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","article-title":"The genetic basis of hepatosplenic T-cell lymphoma","volume":"7","author":"McKinney","year":"2017","journal-title":"Cancer Discov"},{"issue":"7360","key":"2020033111374482800_B5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"2","key":"2020033111374482800_B6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"18","key":"2020033111374482800_B7","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2020033111374482800_B8","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"issue":"49","key":"2020033111374482800_B9","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2020033111374482800_B10","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"2020033111374482800_B11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J Mol Diagn"},{"issue":"4","key":"2020033111374482800_B12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","article-title":"Synergistic drug combinations with a CDK4\/6 inhibitor in T-cell acute lymphoblastic leukemia","volume":"23","author":"Pikman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2020033111374482800_B13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"4","key":"2020033111374482800_B14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2020033111374482800_B15","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0840","article-title":"EZH2 inhibition by tazemetostat results in altered dependency on B-cell activation signaling in DLBCL","volume":"16","author":"Brach","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2020033111374482800_B16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020033111374482800_B17","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","article-title":"Enhancer of zeste homolog 2 (EZH2) inhibitors","volume":"59","author":"Gulati","year":"2018","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1265\/1722814\/advancesadv2019001256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1265\/1722814\/advancesadv2019001256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T16:25:44Z","timestamp":1585671944000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/7\/1265\/454182\/Targeting-EZH2-for-the-treatment-of-hepatosplenic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001256","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]}}}